Innovative LAG-3 Immunotherapy in Oncology and Autoimmune Diseases

When our Chief Scientific Officer, Dr. Frédéric Triebel, first discovered Lymphocyte Activation Gene-3 (LAG-3), he realized there was a novel pathway that could lead to valuable therapeutics for patients by harnessing the power of their own immune systems. This view centered on his findings around the interaction of LAG-3 and one of the central components of how our bodies respond to cancer, autoimmune diseases, and infection - the major histocompatibility complex class II (MHC II) - found on antigen-presenting cells.

Since those discoveries, Immutep has been a pioneer in developing therapeutics that are distinctly designed around the interplay of LAG-3 and MHC II to either stimulate or suppress the immune system to fight cancer or eradicate autoimmune diseases. Today, we have a diversified portfolio of cutting-edge immuno-oncology and targeted LAG-3 immunotherapy including three clinical stage candidates, one pre-clinical candidate, and one candidate that is early-stage.

Oncology Portfolio

  • Igniting the Immune Response via Antigen Presenting Cells (APC)
    Our lead clinical candidate, eftilagimod alpha (efti / IMP321), is a first-in-class soluble LAG-3 protein delivered subcutaneously that uniquely activates APCs (e.g., dendritic cells, monocytes) via a specific subset of MHC II ligands, stimulating both the adaptive & innate immune systems to fight cancer. The broad immune response elicited by efti includes significant increases of various anti-tumor cells and serum biomarkers that corresponds with encouraging outcomes in numerous clinical trials.

  • Blocking LAG-3 On T Cells to Boost an Immune Response
    As a co-inhibitory receptor, LAG-3’s expression on T cells has a negative feedback mechanism that cancer utilizes to hide from the immune system. Immutep designed the world’s first anti-LAG-3 antibody to block LAG-3 and remove the brakes on the immune system to better respond to cancer. Our subsequent efforts led to LAG525 (ieramilimab), the anti-LAG-3 clinical candidate we have out-licensed to Novartis. Today, Immutep continues to innovate in blocking LAG-3 on T cells through a novel, small molecule anti-LAG-3 candidate at the early development stage.

Autoimmune Diseases Portfolio

  • Agonist LAG-3 Antibody
    Immutep has developed the world’s first LAG-3 agonist antibody for autoimmune diseases, called IMP761, which acts upstream on activated T cells to target the root cause of self-antigen-specific T cell induced disease. This pre-clinical candidate is a potential game-changer in how autoimmune diseases are treated.

  • Depleting LAG-3 Antibody
    Immutep has out-licensed the clinical candidate GSK’781 (IMP731), a depleting LAG-3 antibody that removes T cells involved in autoimmune diseases, to GlaxoSmithKline.

For more on the Company’s technology and LAG-3 product portfolio, please see Our Science and our Clinical Pipeline.